HINGHAM, Mass. — May 5, 2026 — Leads & Copy — Microbot Medical Inc. (Nasdaq: MBOT) is experiencing strong interest in its LIBERTY Endovascular Robotic System following its full market release at the recent Society of Interventional Radiology (SIR) annual meeting. The company has secured accounts in key sales territories, including two that participated in the ACCESS-PVI pivotal clinical trial.
The company attributes its growing commercial interest to updated medical guidelines focused on reducing radiation exposure and improving ergonomic challenges that contribute to staffing issues in interventional care.
Microbot Medical will attend the Annual Global Embolization Symposium & Technologies (GEST) Conference in New York City from May 14-17, 2026, to further promote the LIBERTY system. The conference attracts over 1,000 interventional radiologists and interventional oncologists.
The GEST conference participation supports Microbot’s efforts to establish a global commercial infrastructure, further bolstered by the recent appointment of Alon Tamir as Vice President of Sales, EMEA.
Harel Gadot, Chairman, CEO and President, stated that the company is seeing strong momentum post-SIR, adding new accounts and pursuing opportunities across existing and new sales territories. He added that the GEST Conference represents the first major conference featuring the LIBERTY system since its full market release during SIR.
Microbot Medical (NASDAQ: MBOT) focuses on transforming endovascular procedures through advanced robotic technology. Its LIBERTY Endovascular Robotic System is a single-use, remotely operated robotic solution designed for precision, efficiency, and safety.
Microbot Medical is a commercial-stage medical device company. Learn more at the company website and connect on LinkedIn and X.
Source: Microbot Medical
